Search results
Added:
8 months ago
Source:
Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
A novel, selective amylin receptor agonist, eloralintide, has demonstrated significant, dose-dependent weight loss in adults with obesity or overweight, according to the results of a 48-week phase 2 trial (NCT06230523).¹ Amylin-based therapies are an emerging class of promising medications for weight management.²This multicentre, double-blind, randomised, placebo-controlled trial was conducted…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
A new pooled analysis suggests that measures of abdominal adiposity, such as waist-to-height ratio, are better predictors of clinical outcomes than body mass index (BMI) alone in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Obesity is highly prevalent in this patient population and is linked to an increased risk of mortality and disability.This…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
A new study has defined a metabolome-informed body mass index (metBMI) that more accurately reflects adiposity and cardiometabolic risk than the traditional BMI calculation.² The findings, published in Nature Medicine, suggest this multi-omic approach could help identify high-risk individuals whose metabolic dysfunction is not captured by conventional measures.¹MethodologyResearchers developed…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
A novel, once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron, has demonstrated superior weight loss compared to placebo in adults with obesity or overweight and type 2 diabetes, according to results from the ATTAIN-2 trial.¹Orforglipron is an oral, non-peptide, small-molecule GLP-1 receptor agonist, offering a potential alternative to injectable therapies for weight…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: David RamseyAmerican Diabetes Scientific Sessions, 21 June, 2024 – In a Phase III trial (SURMOUNT-OSA,NCT05412004)of patients with moderate-to-severe sleep apnea and obesity, tirzepatide demonstrated significant improvements in both sleep apnea scores as well as cardiometabolic risk factors including body weight, hsCRP and systolic blood pressure.SURMOUNT-OSA investigated tirzepatide’s…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
A pragmatic, scalable approach to obesity implemented in primary care has the potential to curtail population weight gain, according to findings from the PATHWEIGH trial. The study found that a multi-component care process successfully mitigated the weight gain observed with usual care and increased the likelihood of patients receiving weight-related treatment.¹The PATHWEIGH intervention…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
Following the primary analysis of the SELECT trial, which demonstrated that semaglutide reduces major adverse cardiovascular events, a new exploratory analysis suggests the treatment also significantly lowers the rate and duration of hospitalisations in patients with established cardiovascular disease (CVD) and overweight or obesity, but without diabetes.¹MethodologyThis prespecified exploratory…
View more